Document is current
Any future updates will be listed below
-
Authors
Gonzalez Castro, L. Nicolas
Gavish, Avishai
Bussema, Lillian
Mount, Christopher W.
Neftel, Cyril
Nomura, Masashi
Chiocca, E. Antonio
Bi, Wenya Linda
Arnaout, Omar
Barker, Fred G. II
Brown, Justin M.
Jordan, Justin T.
Batchelor, Tracy T.
Stemmer-Rachamimov, Anat
Plotkin, Scott R.
Tirosh, Itay
Suvà, Mario L.
- License Information
-
More Information
Article History
Received: 14 February 2024
Accepted: 20 March 2025
First Online: 11 April 2025
Declarations
:
: This study received ethics approval from the Institutional Review Board of the Dana-Farber / Harvard Cancer Center (DF/HCC Protocol 10- 417). Written informed consent to participate was obtained from all individuals whose tumor samples were included in this study. The research above described is in conformity with the principles of the Helsinki Declaration.
: Not applicable.
: LNGC [Employment (Takeda - spouse), Stock (Takeda - spouse), Consulting (Oakstone Publishing, Elsevier, BMJ Publishing, Prime Education, Servier Laboratories), Research Funding (Merck - to DFCI)]; JTJ [Employment (Elsevier), Stock (Akeila Bio, Navio Theragnostics, The Doctor Lounge), Consulting (Akeila Bio, Alexion Pharmaceuticals, Magnet Biomedicine, Navio Theragnostics, Recursion Pharmaceuticals, Shepherd Therapeutics, Springwork Therapeutics)]; SRP [Cofounder (NF2 therapeutics), Consulting (Akouos)]; MLS [Cofounder (Immunitas Therapeutics), Stock (Immunitas Therapeutics)]. The remaining authors declare that they do not have any competing interests.
